阿贝西利治疗人表皮生长因子受体 2 阴性转移性乳腺癌患者：法国、意大利和西班牙的真实世界研究。

Hospital Universitario Clínico San Cecilio, 18016 Granada, Spain.

Medicine Department, Granada University, 18010, Granada, Spain.

Future Oncol. 2024;20(31):2371-2384. doi: 10.1080/14796694.2024.2368455. Epub 2024 Aug 8.

This real-world study aimed to describe patient and clinical characteristics, treatment patterns and outcomes for patients with HR+/HER2- metastatic breast cancer receiving abemaciclib in France, Italy and Spain. A multicenter chart review was conducted for adult females with HR+/HER2- advanced/metastatic breast cancer who received abemaciclib in routine care. Real-world progression-free survival (rwPFS) was estimated via Kaplan-Meier curves. This study included 151, 173 and 175 patients from France, Italy and Spain, respectively. Abemaciclib was mostly prescribed as first-line therapy concomitantly with hormone therapy. Median rwPFS was >20 months and the 1-year rwPFS rate was >70%. Effectiveness was similar across the three countries and aligns with pivotal studies.

这项真实世界研究旨在描述在法国、意大利和西班牙接受 abemaciclib 治疗的 HR+/HER2-转移性乳腺癌患者的患者和临床特征、治疗模式和结局。对在常规护理中接受 abemaciclib 治疗的 HR+/HER2-晚期/转移性乳腺癌的成年女性进行了多中心病历回顾。通过 Kaplan-Meier 曲线估计真实世界无进展生存期（rwPFS）。本研究分别纳入了来自法国、意大利和西班牙的 151、173 和 175 名患者。abemaciclib 主要作为一线治疗与激素治疗联合使用。中位 rwPFS 超过 20 个月，1 年 rwPFS 率超过 70%。在这三个国家，疗效相似，与关键性研究一致。